‘Game changing’ cancer drug to be withdrawn by manufacturer
Takeda — manufacturer of Exkivity (mobocertinib), which is used to treat a rare form of lung cancer — has announced it intends to withdraw the drug after it did not meet its primary endpoint in a phase III trial.…
Published: 4 October 2023
